Clinical trials: Disruptive Behaviors
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
ADHD, Growth
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
Previous NIH funded Attention Deficit Hyperactivity Disorder (ADHD) trials in children found that daily stimulant therapy produced sustained growth deficits.
- Trial name
- NCT01109849
- Testing
- behavior therapy, Extended release (ER) methylphenidate product, monitoring
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Florida International University
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder
Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study
This proposed research will use randomized control trial (RCT) methodology and compare micronutrients with placebo in 135 children with ADHD.
- Trial name
- MADDY (NCT03252522)
- Testing
- Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
- Where
- 3 sites in United States, Canada
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Attention Deficit Hyperactivity Disorder
Tools to Improve Medication Continuity in Adolescents With ADHD
Medication is an efficacious treatment strategy for adolescents with attention-deficit/hyperactivity disorder (ADHD), however use significantly declines during adolescence when the consequences of ADHD are most severe (e.g.
- Trial name
- NCT04173000
- Testing
- Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software without medication continuity tools
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
This study will determine whether two new psychostimulant medications are more effective, tolerable, and acceptable than two older medications for treating attention deficit hyperactivity disorder.
- Trial name
- NCT00889915
- Testing
- Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH)
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Duke University
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Network Control TMS fMRI
This study uses different types of functional magnetic resonance imagining (fMRI) to generate individual transcranial magnetic stimulation (TMS) targets.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
- Trial name
- NCT05736458
- Testing
- Transcranial Magnetic Stimulation (TMS), High controllability TMS target
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cognition Disorder, Attention Deficit Disorder
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI).
- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Trial name
- DAPET-TBI (NCT02225106)
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Onychophagia
Use of N-Acetylcysteine (NAC) in Fingernail Biting
To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their…
- Trial name
- NCT01993849
- Testing
- N-Acetylcysteine (NAC)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Kevin Gray, MD
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
ADHD, Attention Deficit Hyperactivity Disorder
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
Organizational, time management and planning (OTMP) skills deficits are impairing features of developmental disorders, such as Attention Deficit Hyperactive Disorder (ADHD), which compromise school performance and family…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
- Trial name
- NCT04108273
- Testing
- Organizational Skills Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder
Long-Term, Open Label Atomoxetine Study
To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with…
- Trial name
- NCT00190684
- Testing
- atomoxetine
- Where
- 100 sites in United States, Australia and 12 more
- Volunteers
- 1,553 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
The purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of Attention-Deficit/Hyperactivity…
- Trial name
- ADHD LIFE (NCT00447278)
- Testing
- Atomoxetine, Other standard therapy for ADHD
- Where
- 35 sites in Belgium, France and 7 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
The purpose of this research study is to study a device called an electroencephalograph (EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Trial name
- NCT01063153
- Testing
- Osmotic Release Methylphenidate
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Autistic Disorder, Attention Deficit Disorder With Hyperactivity
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
- Trial name
- NCT00380692
- Testing
- Atomoxetine
- Where
- 8 sites in Netherlands
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Intervention for Teens With ADHD and Substance Use
Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use…
- Trial name
- NCT02502799
- Testing
- Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Florida International University
ADHD, Autism
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
- Trial name
- NCT02255565
- Testing
- Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Seattle Children's Hospital